51. Outcomes of cold snare EMR of nonampullary duodenal adenomas ≥1 cm: a multicenter study.
- Author
-
Wilson N, Abdallah M, Schulman AR, Mosko JD, Saeed A, Kothari S, Kaul V, Kothari TH, Phan J, Kumar A, Tofani C, Kim RE, Westanmo A, Moy BM, Dang F, Canakis A, Sharma N, Muniraj T, Azeem N, and Bilal M
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Aged, Treatment Outcome, Neoplasm Recurrence, Local, Tumor Burden, Aged, 80 and over, Adult, Postoperative Hemorrhage epidemiology, Postoperative Hemorrhage etiology, Duodenal Neoplasms surgery, Duodenal Neoplasms pathology, Endoscopic Mucosal Resection methods, Endoscopic Mucosal Resection adverse effects, Adenoma surgery, Adenoma pathology
- Abstract
Background and Aims: Endoscopic mucosal resection (EMR) with use of electrocautery (conventional EMR) has historically been used to remove large duodenal adenomas; however, use of electrocautery can predispose to adverse events including delayed bleeding and perforation. Cold snare EMR (cs-EMR) has been shown to be safe and effective for removal of colon polyps, but data regarding its use in the duodenum are limited. The aim of this study was to evaluate the efficacy and safety of cs-EMR for nonampullary duodenal adenomas ≥1 cm., Methods: This was a multicenter retrospective study of patients with nonampullary duodenal adenomas ≥1 cm who underwent cs-EMR from October 2014 to May 2023. Patients who received any form of thermal therapy were excluded. Primary outcomes were technical success and rate of recurrent adenoma. Secondary outcomes were adverse events and predictors of recurrence., Results: A total of 125 patients underwent resection of 127 nonampullary duodenal adenomas with cs-EMR. Follow-up data were available in 89 cases (70.1%). The recurrent adenoma rate was 31.5% (n = 28). Adverse events occurred in 3.9% (n = 5), with 4 cases of immediate bleeding (3.1%) and 1 case of delayed bleeding (.8%). There were no cases of perforation. The presence of high-grade dysplasia was found to be an independent predictor of recurrence (odds ratio, 10.9 [95% confidence interval, 1.1-102.1]; P = .036)., Conclusions: This retrospective multicenter study demonstrates that cs-EMR for nonampullary duodenal adenomas is safe and technically feasible with an acceptable recurrence rate. Future prospective studies are needed to directly compare outcomes of cs-EMR with conventional and underwater EMR., Competing Interests: Disclosure The following authors disclosed financial relationships: A. R. Schulman is a consultant for Apollo Endosurgery, Boston Scientific, Olympus, and Microtech and has grant funding through GI Dynamics and Fractyl. A. Kumar is a consultant for Olympus. R. E. Kim is a consultant for Medtronic, Cook Medical, and Apollo Endosurgery. N. Sharma is a consultant for Boston Scientific, Mauna Kea, Steris, Olympus, and Medtronic and is on the advisory board for EndoscopyNow. N. Azeem is a consultant for Boston Scientific. J. D. Mosko is a consultant for Boston Scientific, Pendopharm, Medtronic, and STERIS and is on the advisory board for Fuji. A. Saeed is a consultant for Boston Scientific, Olympus, Endogastric Solutions, and Medtronic. M. Bilal is a consultant for Boston Scientific. All other authors disclosed no financial relationships., (Copyright © 2024 American Society for Gastrointestinal Endoscopy. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF